188 related articles for article (PubMed ID: 1711943)
21. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis.
Chakravarty K; Pountain G; Merry P; Byron M; Hazleman B; Scott DG
J Rheumatol; 1995 Sep; 22(9):1694-7. PubMed ID: 8523347
[TBL] [Abstract][Full Text] [Related]
22. Epitope mapping of antibodies against ferritin heavy chain in giant cell arteritis and polymyalgia rheumatica.
Große K; Schmidt RE; Witte T; Baerlecken NT
Scand J Rheumatol; 2013; 42(3):215-9. PubMed ID: 23682607
[TBL] [Abstract][Full Text] [Related]
23. [Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica].
Yamane T; Yamauchi H; Abe N; Torio N; Shimada R; Senba T; Imaizumi Y; Nomura T
Ryumachi; 2003 Jun; 43(3):544-8. PubMed ID: 12910963
[TBL] [Abstract][Full Text] [Related]
24. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.
van Sleen Y; Boots AMH; Abdulahad WH; Bijzet J; Sandovici M; van der Geest KSM; Brouwer E
Rheumatology (Oxford); 2020 Jan; 59(1):176-184. PubMed ID: 31292652
[TBL] [Abstract][Full Text] [Related]
25. Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study.
Mallya RK; Hind CR; Berry H; Pepys MB
Arthritis Rheum; 1985 Apr; 28(4):383-7. PubMed ID: 2859021
[TBL] [Abstract][Full Text] [Related]
26. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
[TBL] [Abstract][Full Text] [Related]
27. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
[TBL] [Abstract][Full Text] [Related]
28. Fibrin(ogen)olysis in polymyalgia rheumatica and temporal arteritis: preliminary findings on association with disease activity.
Grau RG; Kassan SS; Franks JJ; Kaplan H; Walker SH; Tan EM
Ann Rheum Dis; 1984 Oct; 43(5):721-4. PubMed ID: 6497463
[TBL] [Abstract][Full Text] [Related]
29. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica.
González-Gay MA; García-Porrúa C; Vázquez-Caruncho M
J Rheumatol; 1998 Sep; 25(9):1750-5. PubMed ID: 9733456
[TBL] [Abstract][Full Text] [Related]
30. Laboratory investigations including liver in polymyalgia rheumatica/giant cell arteritis.
Kyle V
Baillieres Clin Rheumatol; 1991 Dec; 5(3):475-84. PubMed ID: 1807822
[TBL] [Abstract][Full Text] [Related]
31. [3 cases of polymyalgia rheumatica (PMR), in which serum amyloid A was a useful index of the disease activity].
Yamane T; Yamauchi H; Imaizumi Y; Senba T
Ryumachi; 2001 Aug; 41(4):756-62. PubMed ID: 11577405
[TBL] [Abstract][Full Text] [Related]
32. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome.
Ellis ME; Ralston S
Ann Rheum Dis; 1983 Apr; 42(2):168-70. PubMed ID: 6847261
[TBL] [Abstract][Full Text] [Related]
33. Secondary (AA-type) amyloidosis in patients with polymyalgia rheumatica.
Escribá A; Morales E; Albizúa E; Herrero JC; Ortuño T; Carreño A; Dominguez-Gil B; Praga M
Am J Kidney Dis; 2000 Jan; 35(1):137-40. PubMed ID: 10620555
[TBL] [Abstract][Full Text] [Related]
34. Giant cell arteritis with an erythrocyte sedimentation rate lower than 50.
Martínez-Taboada VM; Blanco R; Armona J; Uriarte E; Figueroa M; Gonzalez-Gay MA; Rodriguez-Valverde V
Clin Rheumatol; 2000; 19(1):73-5. PubMed ID: 10752506
[TBL] [Abstract][Full Text] [Related]
35. Antibodies to cardiolipin and beta 2 glycoprotein I in patients with polymyalgia rheumatica and giant cell arteritis.
Meyer O; Nicaise P; Moreau S; de Bandt M; Palazzo E; Hayem G; Chazerain P; Labarre C; Kahn MF
Rev Rhum Engl Ed; 1996 Apr; 63(4):241-7. PubMed ID: 8738442
[TBL] [Abstract][Full Text] [Related]
36. Microheterogeneity of acute phase proteins in the differentiation of polymyalgia rheumatica from polymyositis.
Pawlowski T; Aeschlimann A; Kahn MF; Vaith P; Mackiewicz SH; Mueller W
J Rheumatol; 1990 Sep; 17(9):1187-92. PubMed ID: 1705291
[TBL] [Abstract][Full Text] [Related]
37. Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.
Dasgupta B; Duke O; Timms AM; Pitzalis C; Panayi GS
Ann Rheum Dis; 1989 Apr; 48(4):307-11. PubMed ID: 2653244
[TBL] [Abstract][Full Text] [Related]
38. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
[TBL] [Abstract][Full Text] [Related]
39. Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment.
Macchioni P; Boiardi L; Meliconi R; Salvarani C; Grazia Uguccioni M; Rossi F; Pulsatelli L; Facchini A
J Rheumatol; 1994 Oct; 21(10):1860-4. PubMed ID: 7837151
[TBL] [Abstract][Full Text] [Related]
40. [Rheumatic polymyalgia and temporal arteritis. Case contribution and bibliographic review].
Manganelli P; Mercadanti M; Nervetti A; Ambanelli U
Minerva Med; 1987 Mar; 78(5):287-96. PubMed ID: 3822219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
